UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 153,567 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lowered its stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 74.6% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 52,189 shares of the biotechnology company's stock after selling 153,567 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.19% of Arcturus Therapeutics worth $886,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of the stock. Virtus ETF Advisers LLC raised its stake in Arcturus Therapeutics by 38.8% during the 4th quarter. Virtus ETF Advisers LLC now owns 4,051 shares of the biotechnology company's stock valued at $69,000 after purchasing an additional 1,132 shares during the period. KLP Kapitalforvaltning AS bought a new position in Arcturus Therapeutics during the fourth quarter valued at about $71,000. National Bank of Canada FI boosted its stake in shares of Arcturus Therapeutics by 639.6% during the 4th quarter. National Bank of Canada FI now owns 5,532 shares of the biotechnology company's stock worth $94,000 after acquiring an additional 4,784 shares in the last quarter. Kennedy Capital Management LLC boosted its stake in shares of Arcturus Therapeutics by 22.7% during the 4th quarter. Kennedy Capital Management LLC now owns 10,987 shares of the biotechnology company's stock worth $186,000 after acquiring an additional 2,036 shares in the last quarter. Finally, Sherbrooke Park Advisers LLC bought a new stake in shares of Arcturus Therapeutics during the 4th quarter worth about $200,000. Institutional investors own 94.54% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Wells Fargo & Company decreased their target price on Arcturus Therapeutics from $50.00 to $45.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Scotiabank began coverage on Arcturus Therapeutics in a report on Wednesday, May 28th. They issued a "sector outperform" rating and a $32.00 target price for the company. BTIG Research set a $48.00 price target on Arcturus Therapeutics and gave the stock a "buy" rating in a research report on Monday, March 10th. Cantor Fitzgerald restated an "overweight" rating on shares of Arcturus Therapeutics in a research report on Friday, March 7th. Finally, Citigroup reiterated a "buy" rating on shares of Arcturus Therapeutics in a research report on Tuesday, May 13th. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $53.50.

Arcturus Therapeutics Trading Up 1.6%

Shares of NASDAQ:ARCT traded up $0.20 during midday trading on Thursday, hitting $12.64. The company had a trading volume of 313,202 shares, compared to its average volume of 438,933. The stock has a market cap of $342.81 million, a price-to-earnings ratio of -5.69 and a beta of 2.30. Arcturus Therapeutics Holdings Inc. has a 12 month low of $8.04 and a 12 month high of $33.65. The firm has a fifty day simple moving average of $11.69 and a 200 day simple moving average of $14.48.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($0.52) EPS for the quarter, beating analysts' consensus estimates of ($1.58) by $1.06. The company had revenue of $29.38 million for the quarter, compared to analyst estimates of $25.64 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. Equities analysts forecast that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current fiscal year.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.